Dapagliflozin/Metformin Polpharma

Dapagliflozin/Metformin Polpharma combines two oral diabetes medications for blood sugar management. This fixed-dose combination is designed to support glycemic control in adults with type 2 diabetes.

Dapagliflozin/Metformin Polpharma is used to improve blood sugar levels in adults with type 2 diabetes. This combination therapy works by increasing insulin sensitivity and reducing glucose absorption in the kidneys. It is typically prescribed as part of a broader diabetes management plan, which may include diet and exercise.

Common effects of Dapagliflozin/Metformin Polpharma may include urinary tract infections, genital fungal infections, and gastrointestinal discomfort. Some users may experience increased urination or mild hypoglycemia. These effects vary and are not exhaustive; individual experiences may differ.

Handle Dapagliflozin/Metformin Polpharma with care, especially if you have kidney issues, as it may affect renal function. Stay hydrated and monitor blood sugar levels regularly. Consult a healthcare provider before use if you have a history of diabetic ketoacidosis or severe gastrointestinal disease.

Dapagliflozin/Metformin Polpharma may interact with certain medications, including insulin, sulfonylureas, and diuretics. Alcohol consumption should be limited, as it can increase the risk of lactic acidosis. Always inform your healthcare provider about all medications you are taking.